US 9192683
Methods of treating disease with FGFR1 fusion proteins
granted A61KA61K45/06A61P
Quick answer
US patent 9192683 (Methods of treating disease with FGFR1 fusion proteins) held by Five Prime Therapeutics, Inc. expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K45/06, A61P, A61P1/02, A61P1/04